Clinical trial · no report yet · Phase 2
TRIM-EBC
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
- NCT06517212 ↗
- Recruiting
- Baylor Research Institute
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Adjuvant Tirzepatide Plus Standard of Care Endocrine Therapy in Patients With Obesity or Overweight Who Have Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, With Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; Breast Neoplasms; Breast Cancers
- Interventions
- Tirzepatide
- Arms
- tirzepatide · Experimental
- Enrollment
- 48 (estimated)
- Primary outcomes
- ctDNA efficacy
- distant disease-free survival efficacy
- Sponsor
- Baylor Research Institute
- Start
- Nov 26, 2024
- Primary completion
- Aug 31, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06517212 · updated Feb 12, 2026